Business context and reporting period
Ascentage Pharma Group International, a foreign private issuer that files annual reports on Form 20-F, furnished this Form 6-K for September 2026. On September 28, 2026, the Company posted two announcements on the Hong Kong Stock Exchange.
Financial metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial metrics.
Material developments
- The trustee purchased shares for the purpose of the Company’s 2022 RSU Scheme.
- The chairman and an executive director acquired shares.
The furnished filing identifies these announcements as Exhibits 99.1 and 99.2 but does not include their transaction details.
Outlook, risks, and unusual items
No guidance, outlook, risk updates, contingencies, or other unusual items are described in the filing text.
Key facts to verify
- Share quantities, prices, dates, and funding details for both transactions in the exhibits.
- The trustee purchase’s relationship to the 2022 RSU Scheme and any resulting share or award changes.
- The chairman and executive director’s acquisition details and resulting holdings.